{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:17:10Z","timestamp":1789060630263,"version":"build-2803163510"},"reference-count":31,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2019-02397"],"award-info":[{"award-number":["2019-02397"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2022-01018"],"award-info":[{"award-number":["2022-01018"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2023-00356"],"award-info":[{"award-number":["2023-00356"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101053962"],"award-info":[{"award-number":["101053962"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["ALFGBG-71320"],"award-info":[{"award-number":["ALFGBG-71320"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alzheimer Drug Discovery Foundation (ADDF), USA","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831376-C"],"award-info":[{"award-number":["ADSF-21-831376-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831377-C"],"award-info":[{"award-number":["ADSF-21-831377-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831381-C"],"award-info":[{"award-number":["ADSF-21-831381-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-24-1284328-C"],"award-info":[{"award-number":["ADSF-24-1284328-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Programme","award":["JPND2021-00694"],"award-info":[{"award-number":["JPND2021-00694"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S021418\/1"],"award-info":[{"award-number":["MR\/S021418\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hj\u00e4rnfonden, Sweden","award":["FO2022-0270"],"award-info":[{"award-number":["FO2022-0270"]}]},{"name":"the Bluefield Project, Cure Alzheimer\u2019s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor, Hj\u00e4rnfonden, Swede","award":["#FO2022-0270"],"award-info":[{"award-number":["#FO2022-0270"]}]},{"name":"UCL","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,11,22]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Can plasma biomarkers as well as cerebrospinal fluid (CSF) perform in the separation of amyloid-beta-positive (A\u03b2+) vs amyloid-beta-negative (A\u03b2\u2212) groups across an age range seen in an NHS cognitive disorder clinic?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>As part of the routine diagnostic investigation of 111 clinic patients who had contemporaneous blood and CSF samples taken, patients were categorised into A\u03b2+ and A\u03b2\u2212 groups based on their CSF in an A\u03b242\/40 ratio. We then evaluated four single molecule array (Simoa) Quanterix assays, quantifying single plasma analytes and ratios (p-tau217, p-tau217\/A\u03b242 ratio, p-tau181, p-tau181\/A\u03b242 ratio and A\u03b242\/40 ratio) in their ability to distinguish between these groups and the effect of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median (range) age of participants was 66 (55\u201379) years with 48 females (43.2%). The areas under the curve (AUC), not accounting for age, for the ability to discriminate A\u03b2+ from A\u03b2\u2212 groups were plasma p-tau217 AUC=0.94, A\u03b242\/40 AUC=0.78 and p-tau181 AUC=0.77. Combining p-tau217\/A\u03b242 increased the AUC to 0.97. The difference between the groups was influenced by age with less separation in older individuals: a significant negative interaction term between age and group for plasma p-tau217 concentrations (\u22120.037, p=0.013) and p-tau217\/A\u03b242 ratio (\u22120.007, p=0.008).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was variable performance of plasma biomarkers to recapitulate the CSF assay. Both p-tau217 and p-tau217\/A\u03b242 showed excellent promise as surrogates of CSF amyloid status, although with slightly reduced performance in older individuals. There was poorer discriminatory ability for p-tau181 and A\u03b242\/40. Further research is needed to address potential age-related confounds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2024-334122","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T11:45:18Z","timestamp":1734522318000},"page":"566-572","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["How well do plasma Alzheimer\u2019s disease biomarkers reflect the CSF amyloid status?"],"prefix":"10.1136","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-4768","authenticated-orcid":false,"given":"Jemma","family":"Hazan","sequence":"first","affiliation":[{"name":"Division of Psychiatry, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Abel","sequence":"additional","affiliation":[{"name":"UCL, UK Dementia Research Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rosa Grilo","sequence":"additional","affiliation":[{"name":"UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Alawode","sequence":"additional","affiliation":[{"name":"UCL, UK Dementia Research Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Laranjinha","sequence":"additional","affiliation":[{"name":"UCL, UK Dementia Research Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-6405","authenticated-orcid":false,"given":"Amanda J","family":"Heslegrave","sequence":"additional","affiliation":[{"name":"UCL, UK Dementia Research Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-2758","authenticated-orcid":false,"given":"Kathy Y","family":"Liu","sequence":"additional","affiliation":[{"name":"UCL Division of Psychiatry, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2059-024X","authenticated-orcid":false,"given":"Jonathan M","family":"Schott","sequence":"additional","affiliation":[{"name":"Dementia Research Centre, Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[{"name":"UCL Division of Psychiatry, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"UCL, UK Dementia Research Institute, London, UK"},{"name":"Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, Goteborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick C","family":"Fox","sequence":"additional","affiliation":[{"name":"UCL, UK Dementia Research Institute, London, UK"},{"name":"UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"2026060322301059000_96.6.566.1","doi-asserted-by":"publisher","DOI":"10.1192\/bjb.2019.18"},{"key":"2026060322301059000_96.6.566.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0404-6"},{"key":"2026060322301059000_96.6.566.3","unstructured":"Royal College of Psychiatrists DAT, Alzheimer\u2019s Research UK . Are we ready to deliver disease modifying treatments? 2021. Available: https:\/\/www.alzheimersresearchuk.org\/wp-content\/uploads\/2021\/05\/ARUK-Are-we-ready-to-deliver-disease-modifying-treatments_25May21.pdf"},{"key":"2026060322301059000_96.6.566.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.08.003"},{"key":"2026060322301059000_96.6.566.5","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol Med"},{"key":"2026060322301059000_96.6.566.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5"},{"key":"2026060322301059000_96.6.566.7","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12316"},{"key":"2026060322301059000_96.6.566.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2015.05.024"},{"key":"2026060322301059000_96.6.566.9","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040850","article-title":"Development of Alzheimer\u2019s Disease Biomarkers: From CSF- to Blood-Based Biomarkers","volume":"10","author":"Mankhong","year":"2022","journal-title":"Biomedicines"},{"key":"2026060322301059000_96.6.566.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106356"},{"key":"2026060322301059000_96.6.566.11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac333"},{"key":"2026060322301059000_96.6.566.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature25456"},{"key":"2026060322301059000_96.6.566.13","first-page":"e1647","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2026060322301059000_96.6.566.14","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-021-00234-5"},{"key":"2026060322301059000_96.6.566.15","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13026"},{"key":"2026060322301059000_96.6.566.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00665-2"},{"key":"2026060322301059000_96.6.566.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24319-x","article-title":"Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer\u2019s disease in adults with Down syndrome","volume":"12","author":"Lle\u00f3","year":"2021","journal-title":"Nat Commun"},{"key":"2026060322301059000_96.6.566.18","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"key":"2026060322301059000_96.6.566.19","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol Med"},{"key":"2026060322301059000_96.6.566.20","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2020.12134"},{"key":"2026060322301059000_96.6.566.21","doi-asserted-by":"crossref","unstructured":"Ashton NJ , Brum WS , Di Molfetta G , et al . Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer\u2019s disease pathology. medRxiv 2023. doi:10.1101\/2023.07.11.23292493","DOI":"10.1101\/2023.07.11.23292493"},{"key":"2026060322301059000_96.6.566.22","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-022-01822-2"},{"key":"2026060322301059000_96.6.566.23","doi-asserted-by":"crossref","unstructured":"Hazan J , Alston D , Fox NC , et al . Practical application of Alzheimer\u2019s Disease Neuroimaging Initiative plasma P-tau181 reference data to support diagnosis of Alzheimer\u2019s disease. Int J Geriatr Psychiatry 2022;37. doi:10.1002\/gps.5670","DOI":"10.1002\/gps.5670"},{"key":"2026060322301059000_96.6.566.24","doi-asserted-by":"crossref","DOI":"10.1002\/alz.067569","article-title":"Plasma pTau 181 concentrations in middle\u2010aged, community\u2010dwelling, racially and ethnically diverse adults","volume":"18","author":"Brickman","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2026060322301059000_96.6.566.25","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13157"},{"key":"2026060322301059000_96.6.566.26","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2021-003310"},{"key":"2026060322301059000_96.6.566.27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c47cc2"},{"key":"2026060322301059000_96.6.566.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0889-9"},{"key":"2026060322301059000_96.6.566.29","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-023-00371-z","article-title":"The potential impact of clinical factors on blood-based biomarkers for Alzheimer\u2019s disease","volume":"12","author":"Pan","year":"2023","journal-title":"Transl Neurodegener"},{"key":"2026060322301059000_96.6.566.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02074-w"},{"key":"2026060322301059000_96.6.566.31","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"}],"updated-by":[{"DOI":"10.1136\/jnnp-2024-334122corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000}}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-334122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:30:26Z","timestamp":1780551026000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-334122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,5,14]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/jnnp-2024-334122"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-334122","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}